Publications

2020

Stüber T, Monjezi R, Wallstabe L, Kühnemundt J, Nietzer SL, Dandekar G, Wöckel A, Einsele H, Wischhusen J, Hudecek M. J Immunother Cancer (2020) Inhibition of TGF-b-receptor signaling augments the antitumor function of ROR1-specific CAR T-cells against triple-negative breast cancer. 2020;8:e000676. doi:10.1136/jitc-2020-000676

2019

Göttlich C, Wallstabe L, Nelke L, Nietzer S, Schwarz T, Nerreter T, Einsele H, Walles H, Dandekar G*, Hudecek M* (*shared senior authorship). ROR1-specific chimeric antigen receptor T-cells are effective against lung and breast cancer in advanced microphysiologic 3D tumor models. JCI Insight, 2019 Sep 19;4(18). pii: 126345. doi:10.1172/jci.insight.126345

Mestermann K, Rydzek J, Frenz S, Nerreter T, Mades A, Einsele H, Hudecek M. Sci Transl Med. (2019) The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR-T cells. 2019 Jul 3;11(499); doi: 10.1126/scitranslmed.aau5907. PMID: 3127027

Nerreter T, Letschert S, Götz R, Doose S, Danhof S, Einsele H, Sauer M, Hudecek M. Nat Commun. (2019) Super-resolution microscopy reveals ultra-low CD19 expression on maeloma that triggers elimination by CD19 CAR-T. 2019 Jul 17;10(1):3137. doi: 10.1038/s41467-019-10948-w. PMID: 31316055

Rydzek J, Nerreter T, Peng H, Jutz S, Leitner J, Steinberger P, Einsele H, Rader C, Hudecek M. (2019) Chimeric antigen receptor library screening using a novel NF-κB/NFAT reporter cell platform. Molecular Therapy, 2019 Feb 6;27(2):287-299; doi: 10.1016/j.ymthe.2018.11.015. Epub 2018 Nov 20. PMID: 30573301

Querques I, Mades A, Zuliani C, Miskey C, Alb M, Grueso E, Machwirth M, Rausch T, Ivics Z, Hudecek M*, Barabas O * (*Geteilte Letztautorschaft) (2019) A highly soluble Sleeping Beauty transposase improves control of gene insertion. Nature Biotechnology 37, 1502–1512(2019) doi: 10.1038/s41587-019-0291-z

2018

Danhof S, Hudecek M, Smith EL. (2018) CARs and other T cell therapies for MM: The clinical experience. Best Pract Res Clin Haematol., 2018 Jun;31(2):147-157. doi: 10.1016/j.beha.2018.03.002. Epub 2018 Mar 27. PMID: 2990991

Danhof S, Schreder M, Knop S, Rasche L, Strifler S, Löffler C, Gogishvili T, Einsele H, Hudecek M. (2018) Expression of programmed death-1 on lymphocytes in myeloma patients is lowered during lenalidomide maintenance. Haematologica. 2018 Mar;103(3):e126-e129. doi: 10.3324/haematol.2017.178947. Epub 2017 Nov 30. No abstract available. PMID: 29191843

Hudecek M, Ivics Z. (2018) Non-viral therapeutic cell engineering with the Sleeping Beauty transposon system. Curr Opin Genet Dev., 2018 Oct;52:100-108. doi: 10.1016/j.gde.2018.06.003. Epub 2018 Oct 12. PMID: 29957586

Jetani H, Garcia-Cadenas I, Nerreter T, Thomas S, Rydzek J, Meijide JB, Bonig H, Herr W, Sierra J, Einsele H, Hudecek M. (2018) CAR T-cells targeting FLT3 have potent activity against FLT3–ITD+ AML and act synergistically with the FLT3-inhibitor crenolanib.  Leukemia. 2018 Feb 5. doi: 10.1038/s41375-018-0009-0. [Epub ahead of print] PMID: 29472720

Kansagra AJ, Frey NV, Bar M, Laetsch TW, Carpenter PA, Savani BN, Heslop HE, Bollard CM, Komanduri KV, Gastineau DA, Chabannon C, Perales MA, Hudecek M, Aljurf M, Andritsos L, Barrett JA, Bachanova V, Bonini C, Ghobadi A, Gill SI, Hill J, Kenderian S, Kebriaei P, Nagler A, Maloney D, Liu HD, Shah NN, Kharfan-Dabaja MA, Shpall EJ, Mufti GJ, Johnston L, Jacoby E, Bazarbachi A, DiPersio JF, Pavletic SZ, Porter DL, Grupp SA, Sadelain M, Litzow MR, Mohty M, Hashmi SK. (2018) Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Blood and Marrow Transplantation.  Biol Blood Marrow Transplant., 2019 Mar;25(3):e76-e85. doi: 10.1016/j.bbmt.2018.12.068. Epub 2018 Dec 18. PMID: 30576834

Köhler M, Greil C, Hudecek M, Lonial S, Raje N, Wäsch R, Engelhardt M. Cancer. (2018) Current developments in immunotherapy in the treatment of multiple myeloma.  2018 Feb 6. doi: 10.1002/cncr.31243. [Epub ahead of print] Review. PMID: 29409124

Prommersberger S, Jetani H, Danhof S, Monjezi R, Nerreter T, Beckmann J, Einsele H, Hudecek M. (2018) Novel targets and technologies for CAR-T cells in multiple myeloma and acute myeloid leukemia.  Curr Res Transl Med. 2018 Apr 11. pii: S2452-3186(18)30021-7. doi: 10.1016/j.retram.2018.03.006. [Epub ahead of print] No abstract available. PMID: 29655962

Wallstabe L, Mades A, Frenz S, Einsele H, Rader C, Hudecek M. (2018) CAR Tcells targeting ανβ3 integrin are effective against advanced cancer in preclinical models.  Advances in Cell and Gene Therapy, 2018 Sep;1(2). pii: e11. doi: 10.1002/acg2.11. Epub 2018 Jul 10. PMID: 30420973

2017

García-Guerrero E, Gogishvili T, Danhof S, Schreder M, Pallaud C, Pérez-Simón JA, Einsele H, Hudecek M. (2017) Panobinostat induces CD38 upregulation and augments the antimyeloma efficacy of daratumumab. Blood. 2017 Jun 22;129(25):3386-3388. doi: 10.1182/blood-2017-03-770776. Epub 2017 May 5. No abstract available. PMID:28476749

Gogishvili T, Danhof S, Prommersberger S, Rydzek J, Schreder M, Brede C, Einsele H, Hudecek M. (2017) SLAMF7-CAR T cells eliminate myeloma and confer selective fratricide of SLAMF7+ normal lymphocytes. Blood. 2017 Dec 28;130(26):2838-2847. doi: 10.1182/blood-2017-04-778423. Epub 2017 Oct 31. PMID: 29089311

Hudecek M, Izsvák Z, Johnen S, Renner M, Thumann G, Ivics Z. (2017) Going non-viral: the Sleeping Beauty transposon system breaks on through to the clinical side. Crit Rev Biochem Mol Biol. 2017 Aug;52(4):355-380. doi: 10.1080/10409238.2017.1304354. Epub 2017 Apr 12. Review. PMID: 28402189

Peng H, Nerreter T, Chang J, Qi J, Li X, Karunadharma P, Martinez GJ, Fallahi M, Soden J, Freeth J, Beerli RR, Grawunder U, Hudecek M, Rader C. (2017) Mining Naïve Rabbit Antibody Repertoires by Phage Display for Monoclonal Antibodies of Therapeutic Utility.  J Mol Biol. 2017 Sep 15;429(19):2954-2973. doi: 10.1016/j.jmb.2017.08.003. Epub 2017 Aug 14. PMID: 28818634

2016

Hudecek M, Einsele H. (2016) Myeloma CARs are rolling into the clinical arena. Blood. 2016 Sep 29;128 (13):1667-8. doi: 10.1182/blood-2016-08-729467. No abstract available. PMID:27688779

Hudecek M, Gogishvili T, Monjezi R, Wegner J, Shankar R, Kruesemann C, Miskey C, Ivics Z, Schmeer M, Schleef M. (2016) Minicircle-Based Engineering of Chimeric Antigen Receptor (CAR) T Cells.  Recent Results Cancer Res. 2016;209:37-50. doi: 10.1007/978-3-319-42934-2_3. Review. PMID: 28101686

Monjezi R, Miskey C, Gogishvili T, Schleef M, Schmeer M, Einsele H, Ivics Z, Hudecek M. (2016) Enhanced CAR T-cell engineering using non-viral Sleeping Beauty transposition from minicircle vectors.  Leukemia. 2016 Aug 5. doi: 10.1038/leu.2016.180. [Epub ahead of print] PMID:27491640

Paszkiewicz PJ, Fräßle SP, Srivastava S, Sommermeyer D, Hudecek M, Drexler I, Sadelain M, Liu L, Jensen MC, Riddell SR, Busch DH. (2016) Targeted antibody-mediated depletion of murine CD19 CAR T cells permanently reverses B cell aplasia. J Clin Invest. 2016 Nov 1;126 (11):4262-4272. doi: 10.1172/JCI84813. PMID:27760047

Turtle CJ, Hanafi LA, Berger C, Gooley TA, Cherian S, Hudecek M, Sommermeyer D, Melville K, Pender B, Budiarto TM, Robinson E, Steevens NN, Chaney C, Soma L, Chen X, Yeung C, Wood B, Li D, Cao J, Heimfeld S, Jensen MC, Riddell SR, Maloney DG. (2016) CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. J Clin Invest. 2016 Jun 1;126(6):2123-38. doi: 10.1172/JCI85309. Epub 2016 Apr 25.PMID:27111235

Turtle CJ, Hanafi LA, Berger C, Hudecek M, Pender B, Robinson E, Hawkins R, Chaney C, Cherian S, Chen X, Soma L, Wood B, Li D, Heimfeld S, Riddell SR, Maloney DG. (2016) Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells. Sci Transl Med. 2016 Sep 7;8(355):355ra116. doi:10.1126/scitranslmed.aaf8621. PMID:27605551

2015

Berger C, Sommermeyer D, Hudecek M, Berger M, Balakrishnan A, Paszkiewicz PJ, Kosasih PL, Rader C, Riddell SR. (2015) Safety of targeting ROR1 in primates with chimeric antigen receptor-modified T cells. Cancer Immunol Res. 2015 Feb;3(2):206-16. doi: 10.1158/2326-6066. CIR-14-0163. Epub 2014 Oct 29.

Sommermeyer D, Hudecek M, Kosasih PL, Gogishvili T, Maloney DG, Turtle CJ, Riddell SR. (2016) Chimeric antigen receptor-modified T cells derived from defined CD8+and CD4+ subsets confer superior antitumor reactivity in vivo.  Leukemia. 2015 Sep 15. doi: 10.1038/leu.2015.247. [Epub ahead of print]

2014

Riddell SR, Sommermeyer D, Berger C, Liu LS, Balakrishnan A, Salter A, Hudecek M, Maloney DG, Turtle CJ. (2014) Adoptive therapy with chimeric antigen receptor-modified T cells of defined subset composition.  Cancer J. 2014 Mar-Apr;20(2):141-4

2013

Hudecek M, Lupo-Stanghellini MT, Kosasih P, Sommermeyer D, Jensen MC, Rader C, Riddell SR. (2013) Receptor affinity and extracellular domain modifications affect tumor-recognition by ROR1-specific chimeric antigen receptor T cells.  Clin Cancer Res. 2013 Jun 15;19(12):3153-3164.

2012

Turtle CJ, Hudecek M, Jensen MC, Riddell SR. (2012) Engineered T cells for anti-cancer therapy. Curr Opin Immunol. 2012 Oct;24(5):633-9

2010

Hudecek M, Schmitt TM, Baskar S, Lupo-Stanghellini MT, Nishida T, Yamamoto TN, Bleakley M, Turtle CJ, Chang WC, Greisman HA, Wood B, Maloney DG, Jensen MC, Rader C, Riddell SR. (2010) The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor. Blood. 2010 Nov 25;116(22):4532.

2009

Hudecek M, Anderson LD Jr, Nishida T, Riddell SR. (2009) Adoptive T-cell therapy for B-cell malignancies. Expert Rev Hematol. 2009 Oct;2(5):517-32.

Nishida T, Hudecek M, Kostic A, Bleakley M, Warren EH, Maloney D, Storb R, Riddell SR. (2009) Development of tumor-reactive T cells after nonmyeloablative allogeneic hematopoietic stem cell transplant for chronic lymphocytic leukemia. Clin Cancer Res. 2009 Jul 15;15(14):4759-68

Anschrift

Medizinische Klinik I | Hämatologie und Onkologie | Versbacher Straße 5 | 97078 Würzburg | Deutschland